• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

    2/14/23 1:34:02 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VNDA alert in real time by email
    SC 13G/A 1 d403453dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    Vanda Pharmaceuticals Inc.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    921659108

    (CUSIP Number)

    December 30, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Page 1 of 13


    CUSIP No. 921659108

     

      1.    

      Names of Reporting Persons

     

      Macquarie Group Limited

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Sydney, New South Wales Australia

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,323,547 deemed beneficially owned due to reporting person’s ownership of Macquarie Management Holdings Inc., Macquarie Investment Management Business Trust, whose individual holdings are shown on the following forms.

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      2.34%

    12.  

      Type of Reporting Person (See Instructions)

     

      HC

     

    Page 2 of 13


    CUSIP No. 921659108

     

      1.    

      Names of Reporting Persons

     

      Macquarie Management Holdings Inc

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      State of Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      1,288,938

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      1,288,938

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,323,547 deemed beneficially owned due to reporting person’s ownership of Macquarie Investment Management Business Trust

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☒

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      2.34%

    12.  

      Type of Reporting Person (See Instructions)

     

      HC

     

    Page 3 of 13


    CUSIP No. 921659108

     

      1.    

      Names of Reporting Persons

     

      Macquarie Investment Management Business Trust

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☒        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      State of Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      1,288,938

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      1,288,938

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,323,547

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☒

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      2.34%

    12.  

      Type of Reporting Person (See Instructions)

     

      IA

     

    Page 4 of 13


    Item 1.
       (a)      

    Name of Issuer

    Vanda Pharmaceuticals Inc.

       (b)      

    Address of Issuer’s Principal Executive Offices

    2200 Pennsylvania Ave NW Ste 300E, Washington, DC 20037

    Item 2.
       (a)      

    Name of Person Filing

    This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc, Macquarie Investment Management Business Trust,

       (b)      

    Address of Principal Business Office or, if none, Residence

    The principal business address of Macquarie Group Limited, is 50 Martin Place Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 2005 Market Street, Philadelphia, PA 19103.

       (c)      

    Citizenship

    Macquarie Group Limited—Sydney, New South Wales, Australia Corporation

    Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust – incorporated or formed under the laws of the State of Delaware.

       (d)      

    Title of Class of Securities

    Common Stock

       (e)      

    CUSIP Number

    921659108

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)    ☒    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)    ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)    ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
       (k)    ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Page 5 of 13


    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

                       (a)   

    Amount beneficially owned:    

    See responses on the cover page hereto.

      (b)   

    Percent of class:    

    See responses on the cover page hereto.

      (c)    Number of shares as to which the person has:
         (i)   

    Sole power to vote or to direct the vote

    See responses on the cover page hereto.

         (ii)   

    Shared power to vote or to direct the vote

    0

         (iii)   

    Sole power to dispose or to direct the disposition of

    See responses on the cover page hereto.

         (iv)   

    Shared power to dispose or to direct the disposition of

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    See Exhibit A.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Page 6 of 13


    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 7 of 13


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Group Limited   

    February 14, 2023

       Date

    /s/ Michael Wainer

      

    /s/ Charles Glorioso

    Signature    Signature

     

    Michael Wainer

    Associate Director

      

     

    Charles Glorioso

    Division Director

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Management Holdings Inc.   

    February 14, 2023

       Date

    /s/ Brian L. Murray

      
    Signature   
      

     

    Brian L. Murray

    Chief Compliance Officer

      
    Macquarie Investment Management Business Trust   

    February 14, 2023

       Date

    /s/ Brian L. Murray

      
    Signature   
      

     

    Brian L. Murray

    Chief Compliance Officer

      

     

     

    Page 8 of 13

    Get the next $VNDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VNDA

    DatePrice TargetRatingAnalyst
    10/31/2024$18.00Buy
    H.C. Wainwright
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    2/25/2022$24.00 → $12.00Buy → Hold
    Jefferies
    More analyst ratings

    $VNDA
    Financials

    Live finance-specific insights

    See more
    • Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

      Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g

      5/7/25 4:01:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

      Conference Call and Webcast to Follow WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 7, 2025, during which management will discuss the first quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9941754. The conference

      5/2/25 8:46:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

      Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023Full year 2025 revenue expected to grow to $210 to $250 millionPsychiatry portfolio revenue expected to grow to greater than $750 million in 2030Fanapt® MAA for bipolar I disorder and schizophrenia submitted in Q4 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia expected to be submitted in Q1 2025HETLIOZ® MAA for Smith-Magenis syndrome submitted in Q4 2024Tradipitant NDA for motion sickness submitted in Q4 2024Imsidolimab BLA in generalized pustular

      2/13/25 4:01:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VNDA
    Leadership Updates

    Live Leadership Updates

    See more
    • President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/6/25 5:53:21 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Polymeropoulos Mihael Hristos bought $50,200 worth of shares (10,000 units at $5.02), increasing direct ownership by 0.44% to 2,285,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/5/25 5:19:35 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Marketing Officer Wijkstrom Joakim covered exercise/tax liability with 15,520 shares, decreasing direct ownership by 6% to 239,269 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/4/25 4:46:48 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

      WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin

      3/17/23 7:00:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

      Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g

      5/7/25 4:01:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

      WASHINGTON, May 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application (NDA) for Bysanti™ (milsaperidone) has been filed, and that at this time no potential review issues have been identified. The FDA has set February 21, 2026 as the target date for decision on this application. Bysanti™ is a new chemical entity, which was initially identified as an active metabolite of iloperidone. Vanda has discovered that milsaperidone, when administered orally, qu

      5/5/25 8:00:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

      Conference Call and Webcast to Follow WASHINGTON, May 2, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the first quarter 2025 on Wednesday, May 7, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 7, 2025, during which management will discuss the first quarter 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 9941754. The conference

      5/2/25 8:46:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/6/25 5:53:21 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Polymeropoulos Mihael Hristos bought $50,200 worth of shares (10,000 units at $5.02), increasing direct ownership by 0.44% to 2,285,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/5/25 5:19:35 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Polymeropoulos Mihael Hristos covered exercise/tax liability with 95,999 shares and bought $47,050 worth of shares (10,000 units at $4.71), decreasing direct ownership by 4% to 2,275,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/4/25 4:45:52 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

      10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

      5/8/25 7:06:13 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

      5/7/25 4:07:33 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc.

      DEFA14A - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

      4/25/25 4:33:01 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

      H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

      10/31/24 6:31:19 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Vanda Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00

      7/11/24 7:49:37 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals downgraded by Jefferies with a new price target

      Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously

      2/25/22 4:56:52 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FANAPT issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

      4/3/24 4:12:36 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      2/13/24 5:16:07 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      2/13/24 10:53:14 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      2/9/24 9:59:19 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care